Childhood cancer survivors can be at risk for developing the following late effects:
- Overweight/Obesity
- Metabolic Syndrome
- Dyslipidemia
|
If your patient does not have a Survivor Healthcare Plan (SHP), please refer him/her to the appropriate survivor clinic.
Important factors in determining risk for late effects:
- Total dose of radiation
- BMI
- Family history
- Age of patient at time of treatment
- Endocrinopathies
- Gender
- Surgery in suprasellar region
- Prolonged corticosteroid therapy
|
|
Chemotherapy
Table 1
|
Overweight/Obesity
|
Metabolic Syndrome
|
Dyslipidemia
|
|
Alkylating Agents
Busulfan
Carmustine
BCNU
Chlorambucil Cyclophosphamide
Cytoxan
Ifosphamide
Lomustine
CCNU
Mechlorethamine
Melphalan
Procarbazine
Thiotepa
Dacarbazine
DTIC
Temozolomide
|
|
|
|
|
Heavy Metals
Carboplatin
Cisplatin
|
|
|
X
|
|
Antimetabolites
Cytarabine
Ara-C
Mercaptopurine
6MP
Thioguanine
6TG
Methotrexate
|
|
|
|
|
Anthracycline antibiotics
Daunorubicin
Doxorubicin
Adriamycin
Epirubicin
Idarubicin
Mitoxantrone
|
|
|
|
|
Chemotherapy
Table 2
|
Overweight/Obesity
|
Metabolic Syndrome
|
Dyslipidemia
|
|
Anti-tumor antibiotics
Bleomycin
Dactinomycin
|
|
|
|
|
Corticosteroids
Dexamethasone
Decadron
Prednisone
|
|
|
|
|
Enzymes
Asparaginase
|
|
|
|
|
Plant alkaloids
Vincristine
Vinblastine
|
|
|
|
|
Epipodophyllotoxins
Etoposide
VP16
Teniposide
VM26
|
|
|
|
|
Radiation
|
Overweight/Obesity
|
Metabolic Syndrome
|
Dyslipidemia
|
|
All Radiation
|
|
|
|
|
TBI
|
|
X
|
|
|
Head/Brain
|
X
|
X
|
|
|
Neck
|
|
|
|
|
Thorax
|
|
|
|
|
Abdomen
|
|
|
|
|
Pelvis
|
|
|
|
|
Extremity
|
|
|
|
|